Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 141Mesothelioma, Malignant 49Mesothelioma 24Lung Neoplasms 18Unspecified Childhood Solid Tumor, Protocol Specific 15Carcinoma, Non-Small-Cell Lung 14Solitary Fibrous Tumor, Pleural 11Pancreatic Neoplasms 11Esophageal Neoplasms 11Sarcoma 10Ovarian Neoplasms 9Small Cell Lung Carcinoma 8Uterine Cervical Neoplasms 7Stomach Neoplasms 7Colonic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Retinoblastoma 6Neoplasms 6Carcinoma, Ovarian Epithelial 6Breast Neoplasms 6Thymoma 5Salivary Gland Neoplasms 5Fallopian Tube Neoplasms 5Carcinoma, Hepatocellular 5Astrocytoma 5Urinary Bladder Neoplasms 4Osteosarcoma 4Oligodendroglioma 4Neuroblastoma 4Neoplasm Metastasis 4

Interventions

atezolizumab 1Tiragolumab 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Advanced Rare Malignant Solid Neoplasm × Other solid neoplasm × Clear all
NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
12 enrolled
Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡